Design and analysis of random copolymers with antimicrobial activity

具有抗菌活性的无规共聚物的设计与分析

基本信息

  • 批准号:
    8708892
  • 负责人:
  • 金额:
    $ 31.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pathogenic infections represent a persistent threat to human health. The rapid development of resistance to drug therapies creates a continuing need for new anti-infective agents. The proposed research focuses on the development of sequence-random copolymers having a nylon-3 backbone as general, inexpensive antibacterial agents. We will synthesize and characterize a variety of these copolymers designed to mimic the activity of natural host-defense peptides (HDPs), which have been discovered in plants, animals, and humans. HDPs are remarkable for their general ability to halt growth of both Gram negative and Gram positive bacteria while leaving animal cells largely unaffected. The relative inability of bacteria to resist HDPs is usually attributed to a general mode of action involving degradation of bacterial cell membranes. Cationic HDPs are known to form globally amphipathic helices (hydrophobic side chains on one side, charged and other hydrophilic side chains on the opposite side) when they bind to anionic cell membranes. In contrast, the nylon-3 copolymers of interest contain a random sequence of cationic and hydrophobic side chains; they also vary in length. Preliminary work suggests that the random copolymers attack membranes by forming irregular amphipathic surface structures enabled by the flexibility of the nylon-3 backbone. Several of the random nylon-3 copolymers have bacteriostatic properties rivaling those of natural HDPs; they hemolytically attack red blood cells only at high concentration. This work will obtain a better fundamental understanding of how these copolymers degrade membranes in order to inform design improvements. The approach includes both chemical synthesis and detailed analysis of function by single-cell fluorescence imaging. The synthetic methodology enables control of mean copolymer length and the type and percentage of hydrophobic, cationic, and polar side chains. For each individual cell, the analytical methods enable direct correlation in real time of the development of bacterial "symptoms" with the amount of antimicrobial polymer absorbed and the halting of cell growth. The initial work will focus on E. coli and B. subtilis as representative Gram negative and Gram positive species. Observable symptoms include translocation across the outer membrane (OM), lysing of the OM, translocation across the cytoplasmic membrane (CM) and lysing of the CM. The same techniques will determine the special properties of "survivor cells" that are unusually resistant to attack. Time lapse observations after restoration of normal growth medium will reveal which short-term symptoms are sufficient to kill cells, i.e. to prevent subsequent recovery and growth. Detailed mechanistic data from the experiments will feed back into the effort to design cheap and effective antimicrobial polymers. The novel techniques and concepts developed in this work will find wide application in all efforts to design antimicrobial agents involving membrane-based functions. Random copolymers may find applications in the context of antifungal activity, antiplasmodial activity, and lung-surfactant activity as well.
描述(由申请方提供):病原性感染是对人类健康的持续威胁。对药物治疗的耐药性的快速发展产生了对新的抗感染剂的持续需求。拟议的研究重点是开发具有尼龙-3骨架的序列无规共聚物作为通用的廉价抗菌剂。我们将合成和表征各种各样的这些共聚物,旨在模拟天然宿主防御肽(HDPs)的活性,这些肽已在植物,动物和人类中发现。HDPs的显著之处在于其阻止革兰氏阴性和革兰氏阳性细菌生长的一般能力,同时使动物细胞基本上不受影响。细菌抵抗HDPs的相对无能通常归因于涉及细菌细胞膜降解的一般作用模式。 已知阳离子HDPs在与阴离子细胞膜结合时形成全局两亲性螺旋(在一侧上的疏水侧链,在相对侧上的带电和其它亲水侧链)。相比之下,感兴趣的尼龙-3共聚物含有阳离子和疏水侧链的随机序列;它们的长度也不同。初步工作表明,无规共聚物攻击膜形成不规则的两亲性表面结构,使尼龙-3骨干的灵活性。 几种无规尼龙-3共聚物具有与天然HDPs相媲美的抑菌性能;它们仅在高浓度下溶血性攻击红细胞。这项工作将获得更好的基本了解这些共聚物如何降解膜,以通知设计改进。该方法包括化学合成和通过单细胞荧光成像详细分析功能。合成方法能够控制平均共聚物长度以及疏水性、阳离子性和极性侧链的类型和百分比。对于每个单独的细胞,分析方法使得能够在细菌“症状”的发展与所吸收的抗微生物聚合物的量和细胞生长的停止的真实的时间中直接相关。初步工作将集中在E。coli和B.枯草芽孢杆菌作为代表性革兰氏阴性和革兰氏阳性菌种。可观察到的症状包括跨外膜(OM)易位、OM裂解、跨细胞质膜(CM)易位和CM裂解。同样的技术将确定“幸存者细胞”的特殊属性,这些细胞对攻击具有不同寻常的抵抗力。恢复正常生长培养基后的延时观察将揭示哪些短期症状足以杀死细胞,即阻止随后的恢复和生长。来自实验的详细机械数据将反馈到设计廉价有效的抗菌聚合物的努力中。 在这项工作中开发的新技术和概念将发现广泛的应用在所有的努力,设计涉及膜为基础的功能的抗菌剂。无规共聚物可以在抗真菌活性、抗疟原虫活性和肺表面活性剂活性的背景下找到应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SAMUEL H. GELLMAN其他文献

SAMUEL H. GELLMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SAMUEL H. GELLMAN', 18)}}的其他基金

Polymeric Agents for the Treatment of Clostridium difficile Infections
用于治疗艰难梭菌感染的聚合物制剂
  • 批准号:
    9186498
  • 财政年份:
    2015
  • 资助金额:
    $ 31.69万
  • 项目类别:
Polymeric Agents for the Treatment of Clostridium difficile Infections
用于治疗艰难梭菌感染的聚合物制剂
  • 批准号:
    9021375
  • 财政年份:
    2015
  • 资助金额:
    $ 31.69万
  • 项目类别:
Design and analysis of random copolymers with antimicrobial activity
具有抗菌活性的无规共聚物的设计与分析
  • 批准号:
    8041852
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Nylon-3 Copolymers as Synthetic Cell-Adhesive Moieties for Tissue Engineering
Nylon-3 共聚物作为组织工程的合成细胞粘附部分
  • 批准号:
    8240031
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Design and Analysis of Random Copolymers with Antimicrobial Activity
具有抗菌活性的无规共聚物的设计与分析
  • 批准号:
    9196509
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Design and analysis of random copolymers with antimicrobial activity
具有抗菌活性的无规共聚物的设计与分析
  • 批准号:
    8301533
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Design and analysis of random copolymers with antimicrobial activity
具有抗菌活性的无规共聚物的设计与分析
  • 批准号:
    8513354
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Nylon-3 Copolymers as Synthetic Cell-Adhesive Moieties for Tissue Engineering
Nylon-3 共聚物作为组织工程的合成细胞粘附部分
  • 批准号:
    8090829
  • 财政年份:
    2011
  • 资助金额:
    $ 31.69万
  • 项目类别:
Determinants of Fold Stability in Proteins and Analogues
蛋白质和类似物折叠稳定性的决定因素
  • 批准号:
    7926143
  • 财政年份:
    2009
  • 资助金额:
    $ 31.69万
  • 项目类别:
2010 Chemistry and Biology of Peptides Gordon Research Conference
2010年肽化学与生物学戈登研究会议
  • 批准号:
    7804208
  • 财政年份:
    2009
  • 资助金额:
    $ 31.69万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.69万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 31.69万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 31.69万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了